Highly conserved M2e and hemagglutinin epitope-based recombinant proteins induce protection against influenza virus infection (scientific article published on 10 September 2017)

Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant loop region of hepatitis B core antigen: Insertion of multiple copies of M2e increases immunogenicity and protective e

Q58199835

Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes

Q24614628

Treatment and Prevention of Pandemic H1N1 Influenza

Q26748906

Mechanisms of Cross-protection by Influenza Virus M2-based Vaccines

Q26777740

High-throughput recombinant protein expression in Escherichia coli: current status and future perspectives

Q28066811

Universal influenza virus vaccines and therapeutic antibodies

Q30151337

Pandemic preparedness and response--lessons from the H1N1 influenza of 2009.

Q30210593

M2e-based universal influenza A vaccine

Q30227479

Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans.

Q30366045

Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.

Q30371303

An H5N1-based matrix protein 2 ectodomain tetrameric peptide vaccine provides cross-protection against lethal infection with H7N9 influenza virus.

Q30375268

An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses.

Q30384563

An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus

Q30391315

Epidemiology of avian influenza A H7N9 virus in human beings across five epidemics in mainland China, 2013-17: an epidemiological study of laboratory-confirmed case series

Q30402758

Epidemiology of human infections with highly pathogenic avian influenza A(H7N9) virus in Guangdong, 2016 to 2017.

Q33900167

Research and development of universal influenza vaccines

Q34093195

Recombinant protein expression in Escherichia coli: advances and challenges

Q34421339

Current and next generation influenza vaccines: Formulation and production strategies

Q34479463

Influenza vaccines: challenges and solutions

Q35184572

Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin

Q35209148

Epitope Mapping of Avian Influenza M2e Protein: Different Species Recognise Various Epitopes

Q36065047

Evaluation of the immunogenicity and protective effects of a trivalent chimeric norovirus P particle immunogen displaying influenza HA2 from subtypes H1, H3 and B.

Q36970026

Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity

Q37366744

Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines

Q37434385

Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants

Q37512915

Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant

Q39844962

Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Outflanking Antibody Immunodominance on the Road to Universal Influenza Vaccination

Q40140614

Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Toward a Universal Influenza Virus Vaccine: Potential Target Antigens and Critical Aspects for Vaccine Development

Q40140618

Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Potential for a Universal Influenza Vaccine

Q40140624

Protein nanoparticle vaccine based on flagellin carrier fused to influenza conserved epitopes confers full protection against influenza A virus challenge

Q40157020

High immunogenicity of plant-produced candidate influenza vaccine based on the M2e peptide fused to flagellin.

Q40165332

Preliminary Epidemiology of Human Infections with Highly Pathogenic Avian Influenza A(H7N9) Virus, China, 2017.

Q40172945

A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection

Q40503787

High copy numbers and N terminal insertion position of influenza A M2E fused with hepatitis B core antigen enhanced immunogenicity

Q40556139

M2-based influenza vaccines: recent advances and clinical potential

Q40571808

P433

issue

P304

page(s)

641-647

P577

publication date

2017-09-10

P1433

published in

Microbes and Infection

Q15760242

P1476

title

Highly conserved M2e and hemagglutinin epitope-based recombinant proteins induce protection against influenza virus infection

P478

volume

Reverse relations

cites work (P2860)

Q56989454	Combination of M2e peptide with stalk HA epitopes of influenza A virus enhances protective properties of recombinant vaccine
Q54239201	Flagellin-fused protein targeting M2e and HA2 induces potent humoral and T-cell responses and protects mice against various influenza viruses a subtypes.
Q89511342	Plant-Produced Recombinant Influenza A Virus Candidate Vaccine Based on Flagellin Linked to Conservative Fragments of M2 Protein and Hemagglutintin
Q90043367	Protective immunity against influenza virus challenge by norovirus P particle-M2e and HA2-AtCYN vaccines in chickens
Q92905919	Targeting M2e to DEC-205 induces an enhanced serum antibody-dependent heterosubtypic protection against influenza A virus infection
Q47548866	Towards a universal influenza vaccine: different approaches for one goal

P356	DOI	10.1016/J.MICINF.2017.08.010
P932	PMC publication ID	7110499
P698	PubMed publication ID	28903071